NASDAQ · Biotechnology

KALA BIO, Inc. (KALA) Stock

$0.29 -0.91% NASDAQ: KALA Healthcare

Valuation

MetricValue
Price$0.29
Market Cap$5.68M
P/E Ratio-0.01
P/B Ratio1.06
P/S Ratio0.00
EPS (TTM)$-3.31
52-Week High$95.50
52-Week Low$0.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-222.32%
ROA-95.26%
ROCE-232.05%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$11.0M$4.0M$0$0$0
Operating Profit$-109.0M$-81.0M$-39.0M$-40.0M$-39.0M
Net Profit$-143.0M$-45.0M$-42.0M$-39.0M$-27.0M
EPS$-108.32$-1474.00$-867.50$-507.50$-165.50
Op Margin-973.6%-2090.3%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$139.0M$87.0M$56.0M$55.0M$9.0M
Total Liabilities$123.0M$68.0M$48.0M$43.0M$2.0M
Cash$92.0M$70.0M$51.0M$51.0M$8.0M
Borrowings$80.0M$43.0M$36.0M$32.0M$0

Latest News

KALA BIO: Q1 Earnings Snapshot Associated Press · May 15, 2026 KALA BIO Announces Reverse Stock Split GlobeNewswire · May 7, 2026 Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments GlobeNewswire · Apr 28, 2026 Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine GlobeNewswire · Apr 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-108.0M$-79.0M$-28.0M$-29.0M$-32.0M
Investing Cash Flow$70.0M$62.0M$-1.0M$0$0
Financing Cash Flow$2.0M$0$-2.0M$0$0
Net Cash Flow$5.0M$-24.0M$-20.0M$0$-44.0M
Free Cash Flow$-109.0M$-79.0M$-29.0M$-30.0M$-32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.82
FCF Yield-266.77%
Quick Ratio6.88
Interest Coverage-19.01
Return 1Y-99.62%
Return 3Y-99.86%
Return 5Y-99.99%

Ownership

Insiders Held1.29%
Institutions Held0.64%
Institutions Float Held0.65%
Institutional HolderSharesReport Date
Renaissance Technologies, LLC8,3502026-03-31
Citadel Advisors Llc5,6332026-03-31
Geode Capital Management, LLC5,2212026-03-31
Virtu Financial LLC3,0442026-03-31
Adar1 Capital Management, LLC 2,8302026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABPAbpro Corporation $0.52 — -0.02 $1.06M 0.00%
AIMAIM ImmunoTech Inc. $0.18 +0.22% -0.05 $7.05M 0.00%
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
ENSCEnsysce Biosciences, Inc. $0.53 +15.07% -0.16 $8.10M 0.00%
IBOImpact BioMedical, Inc. $4.33 +5.35% -4.48 $36.99M 0.00%

About KALA BIO, Inc.

KALA BIO, Inc. is led by CEO Avi Minkowitz, employs 38 people, headquartered in US, publicly traded since 2017.

KALA BIO, Inc. (KALA) stock trades at $0.29 with a market capitalization of $5.68M. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of 1.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.29 and $95.50, and currently trades 99.7% below its 52-week high.

On profitability, KALA BIO, Inc. generates a return on equity (ROE) of -222.32%, return on capital employed of -232.05%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides